BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

MabThera regulatory update

Roche disclosed in its 4Q10 earnings that MabThera rituximab was approved in Switzerland for first-line maintenance treatment of follicular lymphoma in patients who have responded to induction therapy. MabThera is already approved in the EU for the indication, as well as to treat non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA). Biogen Idec and Roche's Genentech unit co-market the chimeric mAb against CD20 as Rituxan in...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >